CWRUObserver.com - Financial News and Headlines - NYSE, Nasdaq, OTC's

[cavan]

CGCP .72 Cardiogenesis Sets Date for 2004 Fourth Quarter and Year-End Results Announcement and Conference Call
Monday February 7, 7:30 am ET


FOOTHILL RANCH, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, announced that it will release its financial results for the fourth quarter and year-ended December 31, 2004, before the market opens on Thursday, March 3, 2005. That same day, at 12:30 p.m. EST (9:30 a.m. PST), Cardiogenesis' senior management will host a conference call which will be broadcast live over the Internet to discuss the Company's results for the quarter and comment on the current progress of the business.
Those interested in listening to the live webcast of the conference call may do so by going to the Company's website at www.cardiogenesis.com. Webcast participants are encouraged to go to the website at least 15 minutes prior to the start of the call to register and, if necessary, download any needed audio software. A replay of the call will also be accessible at www.cardiogenesis.com for seven days starting shortly after the live webcast.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.

For more information on the Company and its products, please visit the Cardiogenesis web site at www.cardiogenesis.com.

With the exception of historical information, the statements set forth above include